ProCE Banner Activity

CE / CME

Strategies for Addressing Treatment Challenges and Health Inequities in IBD

Multimedia

Renowned experts in inflammatory bowel disease discuss the latest insights about evidence-based treatment strategies, individualized care, and addressing challenges of health inequity for patients with IBD.

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Nurses: 1.50 Nursing contact hours

Released: June 24, 2022

Expiration: June 23, 2023

No longer available for credit.

Share

Faculty

Anita Afzali

Anita Afzali, MD, MPH, MHCM, FACG, AGAF

Professor of Clinical Medicine
Division of Digestive Diseases
Executive Vice Chair
Department of Internal Medicine
Associate Chief Medical Officer
University of Cincinnati, UC Health System
Co-Founder
The Scrubs & Heels Foundation
Cincinnati, Ohio

David Hudesman

David Hudesman, MD, FACG, AGAF

Associate Professor of Medicine
Gastroenterology
NYU School of Medicine
Co-Director
Inflammatory Bowel Disease Center at NYU Langone
Gastroenterology
NYU Langone Health
New York, New York

 

Millie D. Long

Millie D. Long, MD, MPH, FACG, AGAF

Professor of Medicine
Director,
Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. 

Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

This program is intended for primary care professionals, including physicians, physician assistants, and other healthcare professionals who manage patients with IBD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Detail recent advances in the IBD treatment landscape
  • Apply strategies to individualize treatment plans for patients with CD and UC
  • Implement strategies to reduce health inequities among patients with IBD

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Anita Afzali, MD, MPH, MHCM, FACG, AGAF

Professor of Clinical Medicine
Division of Digestive Diseases
Executive Vice Chair
Department of Internal Medicine
Associate Chief Medical Officer
University of Cincinnati, UC Health System
Co-Founder
The Scrubs & Heels Foundation
Cincinnati, Ohio

Anita Afzali, MD, MPH, MHCM, FACG, AGAF: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Eli Lilly, IBD Horizons, Janssen, Pfizer, Takeda.

Faculty Disclosure

Primary Author

David Hudesman, MD, FACG, AGAF

Associate Professor of Medicine
Gastroenterology
NYU School of Medicine
Co-Director
Inflammatory Bowel Disease Center at NYU Langone
Gastroenterology
NYU Langone Health
New York, New York

 

David Hudesman, MD, FACG, AGAF, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Janssen, Pfizer, Takeda, and UCB and funds for research support from Janssen and Pfizer.

Millie D. Long, MD, MPH, FACG, AGAF

Professor of Medicine
Director,
Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Millie D. Long, MD, MPH, FACG, AGAF, has disclosed that she has received consultant/advisor fees from AbbVie, Bristol-Myers Squibb, Calibr, Lilly, Genentech, Janssen, Pfizer, Prometheus, Roche, Takeda, Theravance, and Target Pharmasolutions.

Staff Disclosure

Staff

Ruth Cohen,

Ruth Cohen Cooper, CHCP, has no relevant financial relationships to disclose.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant financial relationships to disclose.

Laurie Rosales, MS, APRN-CNP

Laurie Rosales, MS, APRN-CNP, has no relevant financial relationships to disclose.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until June 23, 2023. PAs should only claim commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 24, 2022, through June 23, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve learners’ knowledge and competence regarding recent advances in therapy, individualized IBD management, and health inequities affecting patients with IBD.